August 1, 2015
Recommended Topic Related To:

Depo-Provera

"The U.S. Food and Drug Administration today announced that it has approved an amended application submitted by Teva Women's Health, Inc. to market Plan B One-Step (active ingredient levonorgestrel) for use without a prescription by women 15 years"...

Depo-Provera




Side Effects
Interactions

SIDE EFFECTS

See PRECAUTIONS for possible adverse effects on the fetus

Reproductive System and Breast Disorders

Nervous System Disorders

Psychiatric Disorders

  • nervousness
  • euphoria
  • mental depression
  • insomnia

General Disorders and Administration Site Conditions

Investigations

  • change in weight (increase or decrease)

Hepatobiliary Disorders

Skin and Subcutaneous Tissue Disorders

Immune System Disorders

Gastrointestinal Disorders

  • nausea

Endocrine Disorders

  • corticoid-like effects (e.g., Cushingoid syndrome)

Metabolism and Nutrition Disorders

In a few instances there have been undesirable sequelae at the site of injection, such as residual lump, change in color of skin, or sterile abscess.

A statistically significant association has been demonstrated between use of estrogen-progestin combination drugs and pulmonary embolism and cerebral thrombosis and embolism. For this reason patients on progestin therapy should be carefully observed. There is also evidence suggestive of an association with neuro-ocular lesions, e.g. retinal thrombosis and optic neuritis.

The following adverse reactions have been observed in patients receiving estrogenprogestin combination drugs:

The following laboratory results may be altered by the use of estrogen-progestin combination drugs:

  • increased sulfobromophthalein retention and other hepatic function tests
  • coagulation tests: increase in prothrombin factors VII, VIII, IX, and X
  • metyrapone test
  • pregnanediol determinations
  • thyroid function: increase in PBI, and butanol extractable protein bound iodine and decrease in T3 uptake values

Read the Depo-Provera (medroxyprogesterone) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Aminoglutethimide administered concomitantly with DEPO-PROVERA Sterile Aqueous Suspension may significantly depress the serum concentrations of medroxyprogesterone acetate. DEPO-PROVERA users should be warned of the possibility of decreased efficacy with the use of this or any related drugs.

In Vitro

Medroxyprogesterone acetate is metabolized primarily by hydroxylation via the CYP3A4. Though no formal drug interaction trials have been conducted, concomitant administration of strong CYP3A inhibitors is expected to increase concentrations of medroxyprogesterone acetate, whereas the concomitant administration of strong CYP3A inducers is expected to decrease medroxyprogesterone acetate concentrations. Therefore, coadministration with strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort) should be avoided.

Laboratory Test Interactions

The pathologist should be advised of progestin therapy when relevant specimens are submitted. The following laboratory tests may be affected by progestins including DEPOPROVERA Sterile Aqueous Suspension:

  1. Plasma and urinary steroid levels are decreased (e.g. progesterone, estradiol, pregnanediol, testosterone, cortisol).
  2. Gonadotropin levels are decreased.
  3. Sex-hormone binding globulin concentrations are decreased.
  4. Protein bound iodine and butanol extractable protein bound iodine may increase. T3 uptake values may decrease.
  5. Coagulation test values for prothrombin (Factor II), and Factors VII, VIII, IX, and X may increase.
  6. Sulfobromophthalein and other liver function test values may be increased.
  7. The effects of medroxyprogesterone acetate on lipid metabolism are inconsistent. Both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol have been observed in studies.

Read the Depo-Provera Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 6/29/2015
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions

Depo Provera - User Reviews

Depo Provera User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Depo Provera sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.